<DOC>
	<DOCNO>NCT02278341</DOCNO>
	<brief_summary>This study conduct explore new therapy anemia patient end stage renal disease ( ESRD ) dialysis . Anemia reduce number red blood cell hemoglobin . Hemoglobin ( contain iron ) important transport oxygen blood . The purpose study evaluate roxadustat effective safe maintenance treatment anemia ESRD patient stable dialysis . Roxadustat compare epoetin alfa darbepoetin alfa , commercially available medicine treatment anemia .</brief_summary>
	<brief_title>Roxadustat Treatment Anemia End Stage Renal Disease ( ESRD ) Patients Stable Dialysis</brief_title>
	<detailed_description>This study consist three study period follow : - Screening Period : 6 week - Treatment Period : 104 week - Follow-up Period : 4 week</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Main Inclusion : Subject stable hemodialysis ( HD ) , hemodiafiltration ( HDF ) peritoneal dialysis ( PD ) treatment mode dialysis ≥4 month prior randomization . Subject IV SC epoetin IV SC darbepoetin alfa treatment ≥8 week prior randomization stable weekly dos ( 4 week prior randomization ) . Mean subject 's three recent Hb value , measure central laboratory , Screening Period . Subject 's alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤3 x upper limit normal ( ULN ) , total bilirubin ( TBL ) ≤1.5 x ULN . Main Exclusion : Subject receive red blood cell ( RBC ) transfusion within 8 week prior randomization . Subject know hereditary hematologic disease thalassemia sickle cell anemia , pure red cell aplasia , know cause anemia Chronic Kidney Disease ( CKD ) . Subject myocardial infarction , acute coronary syndrome , stroke , seizure , thrombotic/thromboembolic event ( e.g. , deep vein thrombosis pulmonary embolism ) within 12 week prior randomization . Subject uncontrolled hypertension , opinion investigator , within 2 week prior randomization . Subject history malignancy , except follow : cancer determine cured remission ≥5 year , curatively resect basal cell squamous cell skin cancer , cervical cancer situ , resect colonic polyp . Subject prior organ transplant ( explanted ) , subject schedule organ transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ASP1517</keyword>
	<keyword>FG-4592</keyword>
	<keyword>Anemia</keyword>
	<keyword>End Stage Renal Disease ( ESRD )</keyword>
	<keyword>Erythropoetin Stimulating Agents ( ESAs )</keyword>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Hematopoetic Agents</keyword>
	<keyword>HIF-PH inhibitor</keyword>
	<keyword>Hemoglobin</keyword>
	<keyword>Dialysis</keyword>
	<keyword>roxadustat</keyword>
</DOC>